Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
October 25, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease
April 13, 2016 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015
October 12, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Appoints Jennifer Panagoulias as Vice President of Regulatory Affairs
September 01, 2015 07:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Initiates Second Phase 3 Clinical Study of Investigational Drug Vonapanitase
August 12, 2015 07:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Appoints Scott Toner as Senior Vice President of Marketing
June 02, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at Upcoming ERA-EDTA Annual Congress
May 22, 2015 07:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 22, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at Two International Vascular Access Conferences
April 13, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...